BR112023003481A2 - Uso de fenretinida ou análogo do mesmo para tratar fibrose pulmonar - Google Patents
Uso de fenretinida ou análogo do mesmo para tratar fibrose pulmonarInfo
- Publication number
- BR112023003481A2 BR112023003481A2 BR112023003481A BR112023003481A BR112023003481A2 BR 112023003481 A2 BR112023003481 A2 BR 112023003481A2 BR 112023003481 A BR112023003481 A BR 112023003481A BR 112023003481 A BR112023003481 A BR 112023003481A BR 112023003481 A2 BR112023003481 A2 BR 112023003481A2
- Authority
- BR
- Brazil
- Prior art keywords
- pulmonary fibrosis
- phenretinide
- analogue
- treat pulmonary
- fenretinide
- Prior art date
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title abstract 3
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 abstract 2
- 229950003662 fenretinide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069881P | 2020-08-25 | 2020-08-25 | |
| PCT/CA2021/051148 WO2022040782A1 (en) | 2020-08-25 | 2021-08-19 | Use of fenretinide or an analogue thereof to treat pulmonary fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003481A2 true BR112023003481A2 (pt) | 2023-05-09 |
Family
ID=80352354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003481A BR112023003481A2 (pt) | 2020-08-25 | 2021-08-19 | Uso de fenretinida ou análogo do mesmo para tratar fibrose pulmonar |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230310352A1 (https=) |
| EP (1) | EP4203931A4 (https=) |
| JP (1) | JP2023539847A (https=) |
| KR (1) | KR20230079054A (https=) |
| CN (1) | CN116437904A (https=) |
| AU (1) | AU2021329999A1 (https=) |
| BR (1) | BR112023003481A2 (https=) |
| CA (1) | CA3128648A1 (https=) |
| MX (1) | MX2023002347A (https=) |
| WO (1) | WO2022040782A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250142485A (ko) | 2024-03-22 | 2025-09-30 | 경희대학교 산학협력단 | 폐섬유증 예방 또는 치료용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011127164A2 (en) * | 2010-04-08 | 2011-10-13 | Fate Therapeutics, Inc. | Pharmaceutical compositions to treat fibrosis |
| TWI658830B (zh) * | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US10406127B2 (en) * | 2014-07-25 | 2019-09-10 | Laurent Pharmaceuticals | Solid oral formulation of fenretinide |
-
2021
- 2021-08-19 JP JP2023512721A patent/JP2023539847A/ja active Pending
- 2021-08-19 KR KR1020237010037A patent/KR20230079054A/ko active Pending
- 2021-08-19 EP EP21859444.8A patent/EP4203931A4/en not_active Withdrawn
- 2021-08-19 AU AU2021329999A patent/AU2021329999A1/en not_active Abandoned
- 2021-08-19 US US18/022,611 patent/US20230310352A1/en active Pending
- 2021-08-19 WO PCT/CA2021/051148 patent/WO2022040782A1/en not_active Ceased
- 2021-08-19 MX MX2023002347A patent/MX2023002347A/es unknown
- 2021-08-19 CA CA3128648A patent/CA3128648A1/en active Pending
- 2021-08-19 CN CN202180072942.9A patent/CN116437904A/zh active Pending
- 2021-08-19 BR BR112023003481A patent/BR112023003481A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022040782A1 (en) | 2022-03-03 |
| EP4203931A4 (en) | 2024-11-13 |
| JP2023539847A (ja) | 2023-09-20 |
| KR20230079054A (ko) | 2023-06-05 |
| EP4203931A1 (en) | 2023-07-05 |
| MX2023002347A (es) | 2023-04-20 |
| CN116437904A (zh) | 2023-07-14 |
| US20230310352A1 (en) | 2023-10-05 |
| AU2021329999A1 (en) | 2023-03-23 |
| CA3128648A1 (en) | 2022-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092343A1 (ru) | Лечение гнойного гидраденита с использованием ингибиторов jak | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| EA202191177A1 (ru) | 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8 | |
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| EP4424367A3 (en) | Treatment of hair loss disorders with deuterated jak inhibitors | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| BR112023003481A2 (pt) | Uso de fenretinida ou análogo do mesmo para tratar fibrose pulmonar | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| BR112022017637A2 (pt) | Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas | |
| ECSP20055797A (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
| WO2020101790A3 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| BR112021017198A2 (pt) | Uso de vibegron para tratar bexiga hiperativa | |
| EP4017496C0 (en) | Formulations intended for use in the prevention and/or treatment of peripheral neuropathology and its associated diseases | |
| MX2020010651A (es) | Regímenes de dosificación para el tratamiento de trastornos proliferativos. | |
| EA202091933A1 (ru) | Композиция для предупреждения и лечения нарушений роста волос | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria | |
| WO2019017676A3 (ko) | 에틸바닐린을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
| BR112022020193A2 (pt) | Métodos de tratamento de infecções por sars-cov-2 |